Reviewing their prospectus, they were originally not planning to market a Ga68-PSMA-11 imaging product:TLX-591 imagingis used to confi rm therapeutic targeting during treatment and to calculatethe patient dose, however Telix is not developing a commercial imagingproduct based on TLX-591 as there are numerous other clinical solutions todiagnostically image PSMA either in development or early commercialisation. [prospectus p14]
Does anyone have any understanding of why it's now such an attractive opportunity? Have the other companies in 'early commercialisation' given up?
Ann: Non-Deal Roadshow Presentation March-April 2019, page-9
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$23.33 |
Change
-0.270(1.14%) |
Mkt cap ! $6.278B | |||
| Open | High | Low | Value | Volume |
| $23.50 | $23.64 | $23.25 | $3.814M | 162.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 398 | $23.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $23.35 | 871 | 7 |
View Market Depth
| Last trade - 10.59am 27/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |
